Loss-of-function screen in rhabdomyosarcoma identifies CRKL-YES as a critical signal for tumor growth

C. L. Yeung, V. N. Ngo, P. J. Grohar, F. I. Arnaldez, A. Asante, X. Wan, J. Khan, S. M. Hewitt, C. Khanna, L. M. Staudt, L. J. Helman

Research output: Contribution to journalArticlepeer-review

29 Scopus citations

Abstract

To identify novel signaling pathways necessary for rhabdomyosarcoma (RMS) survival, we performed a loss-of-function screen using an inducible small hairpin RNA (shRNA) library in an alveolar and an embryonal RMS cell line. This screen identified CRKL expression as necessary for growth of alveolar RMS and embryonal RMS both in vitro and in vivo. We also found that CRKL was uniformly highly expressed in both RMS cell lines and tumor tissue. As CRKL is a member of the CRK adapter protein family that contains an SH2 and two SH3 domains and is involved in signal transduction from multiple tyrosine kinase receptors, we evaluated CRKL interaction with multiple tyrosine kinase receptor signaling pathways in RMS cells. While we saw no interaction of CRKL with IGFIR, MET or PI3KAKT/mTOR pathways, we determined that CRKL signaling was associated with SRC family kinase (SFK) signaling, specifically with YES kinase. Inhibition of SFK signaling with dasatinib or another SFK inhibitor, sarcatinib, suppressed RMS cell growth in vitro and in vivo. These data identify CRKL as a novel critical component of RMS growth. This study also demonstrates the use of functional screening to identify a potentially novel therapeutic target and treatment approach for these highly aggressive pediatric cancers.

Original languageEnglish (US)
Pages (from-to)5429-5438
Number of pages10
JournalOncogene
Volume32
Issue number47
DOIs
StatePublished - Nov 1 2013
Externally publishedYes

Keywords

  • CRKL
  • Dasatinib
  • Rhabdomyosarcoma
  • SRC
  • YES

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Fingerprint

Dive into the research topics of 'Loss-of-function screen in rhabdomyosarcoma identifies CRKL-YES as a critical signal for tumor growth'. Together they form a unique fingerprint.

Cite this